Life Sciences Pitch Event

Wharton Alumni Angels has invited four(4) Life Sciences companies to pitch to WAA Members on Wednesday, 20-Nov-2024 from 4pm - 6:00pm PT // 7pm - 9:00pm ET.  Three of the four companies are focused on treating Neurological Diseases in innovative ways and the third on oncology.  This event will be recorded and posted.

Each company will be allotted a total of 20 minutes for their pitch presentation and Q&A.

This event is open to both Wharton Alumni Angels Members and non-Members - - Feel free to forward to interested parties.

Attendees are invited and encouraged to participate in the post pitch discussion following the last presentation.

Selected companies are listed below.  Click on their company logo to visit their website.

Zoom joining information will be sent upon registering for this event.

PROPOSED AGENDA:

Alleo Labs is redefining neurological diseases as a spectrum, combining AI and drug discovery to develop precise meds.

⭐ Sourced by James Carroll

• PROBLEM: Despite decades of research, common brain disorders like Alzheimer’s and Parkinson’s still lack effective therapies. Traditional approaches have treated these complex diseases as single disease, overlooking shared underlying mechanisms. One critical hallmark we’ve identified is neuroinflammation—a key driver across these disorders = $91B TAM
• SOLUTION: Alleo tackles neuroinflammation with a groundbreaking approach that goes beyond conventional therapies. Using advanced AI for patient stratification, target discovery, and small molecule design, Alleo has developed ALO-001, a potential first-in-class, oral, brain-penetrant DUB inhibitor. This lead candidate is engineered to reduce neuroinflammation
• Pitch Deck
• Deal Terms
  • Raising a round of $1,400,000
  • Premoney valuation of $12M
  • 20% discount upon conversion
• Submit due diligence questions
• Dealum
• Slack: 1-alleo

Biotech developing evergreen transformative drug platform to cure lethal diseases using network computational technology

⭐ Sourced by James Carroll

• PROBLEM: There is a profound lack of treatment options for Huntington’s Disease, a lethal neurodegenerative disorder with no cure, which we can uniquely treat with our multi-target drug COR800 discovered using our platform. In addition to Huntington’s Disease, we have emerging programs to address unmet needs in other neurodegenerative diseases and cancer.
• SOLUTION: Using our network-based technology, we identified that neurons die in Huntington’s Disease because a family of proteins named HOX acts abnormally to inhibit thousands of genes required for neurons to function properly. We developed the COR800 drug to block the action of this HOX family and prevent it from killing neurons at any disease grade.
• Pitch Deck
• Deal Terms:
  • Raising $1.5M
  • SAFE
  • 20% discount
• Submit due diligence questions
• Dealum
• Slack: 1-core-bio

Develop multi-modal designer oncology drugs with improved efficacy and reduced toxicity using texaphyrin technology.

⭐ Sourced by Bill Kriebel

• PROBLEM: Ovarian cancer is the leading cause of gynecological cancer mortality worldwide. Platinum-based drugs are widely used, however 80-90% of women diagnosed with advanced disease will develop platinum resistance. Clinical utility is limited by multiple resistance factors that prevent wt p53 activation by traditional cisplatin/carboplatin treatment.
• SOLUTION: InnovoTEX is developing an innovative drug discovery platform to identify and design targeted therapies that are well-tolerated, localize to solid tumors, and overcome platinum resistance targeting a unique mechanism known as ribosomal biosynthesis stress that induces wt-p53 activation and circumvents platinum resistance caused by DNA damage.
• Pitch Deck
• Deal Terms: 
  • Investment vehicle – seed preferred equity
  • Terms - $7.5M pre-money, $25K minimum, tiered warrant schedule
  • Max allocation – no maximum cap on investment
• Submit due diligence questions
• Dealum
• Slack: 1-innovotex

Origami is developing curative medicines for neurodegenerative diseases caused by toxic protein misfolding.

⭐ Sourced by James Carroll

• PROBLEM: Huntington’s disease (HD) is a genetic, progressive, highly debilitating and terminal neurodegenerative disease. HD is characterized by motor, behavioral and cognitive deficits, depriving >185,000 patients worldwide of their movement and thought processes. Despite $2.8B spent on drugs for HD in 2021 alone, there are no effective treatments for HD.
• SOLUTION: Origami’s oral drug eliminates the toxic mutant protein that causes Huntington’s disease while sparing the normal protein. In doing so, disease symptoms are prevented or halted and normal function will be restored. Patients who would be plagued by Huntington’s disease will not become symptomatic and will live healthy productive lives.
• Pitch Deck
• Deal Terms:
  • Type of investment: SAFE
  • Summary of Deal Terms: 20% discount, 12M post-money valuation
  • Maximum amount allocated to WAA: up to $1.5M
• Submit due diligence questions
• Dealum
• Slack: 1-oragami-therapeutics

----------

Wharton Alumni Angels is not a venture fund, an investment bank, a broker/dealer, investment clearing‐house, or an investment advisor. Wharton Alumni Angels is not registered with the U.S. Securities Exchange Commission or any other state’s or nation’s securities commission. For tax, compliance, reporting, legal or other requirements, it is highly recommended that members seek appropriate professional help. No representation or warranty is made as to the accuracy or completeness of the information provided by Wharton Alumni Angels or companies presenting investment opportunities. Wharton Alumni Angels presumes that any offering conducted by companies is a private placement and does not involve a public solicitation of investment.